Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samit Ghosal

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Scientific Reports|September 26, 2020
Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trialsBinayak Sinha, Samit Ghosal
Diabetes Research and Clinical Practice|February 23, 2019
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failureBinayak Sinha, Samit Ghosal
Diabetes & Metabolic Syndrome|January 3, 2017
Secondary cvd prevention-Lipid modification strategies: A critical analysisSamit Ghosal, Binayak Sinha
Journal of Diabetes Research|December 10, 2015
Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOSSamit Ghosal, Binayak Sinha
Diabetes & Metabolic Syndrome|March 26, 2014
India suspends pioglitazone: is it justified?S M Sadikot, Samit Ghosal
The Journal of the Association of Physicians of India|August 24, 2017
Consensus on Bridges for Barriers to Insulin TherapySanjay Kalra, Samit Ghosal, Parag Shah
Scientific Reports|November 12, 2021
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)Samit Ghosal, Debasis Datta, Binayak Sinha
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 8, 2021
Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetesBinayak Sinha, Debasis Datta, Samit Ghosal
World Journal of Diabetes|November 1, 2016
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromeSanjay Chatterjee, Samit Ghosal, Saurav Chatterjee
Journal of Clinical Medicine|October 28, 2023
The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled TrialsSamit Ghosal, Shamita Ghosal, Anuradha Ghosal
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Scientific Reports|September 26, 2020
Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trialsBinayak Sinha, Samit Ghosal
Diabetes Research and Clinical Practice|February 23, 2019
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failureBinayak Sinha, Samit Ghosal
Diabetes & Metabolic Syndrome|January 3, 2017
Secondary cvd prevention-Lipid modification strategies: A critical analysisSamit Ghosal, Binayak Sinha
Journal of Diabetes Research|December 10, 2015
Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOSSamit Ghosal, Binayak Sinha
Diabetes & Metabolic Syndrome|March 26, 2014
India suspends pioglitazone: is it justified?S M Sadikot, Samit Ghosal
The Journal of the Association of Physicians of India|August 24, 2017
Consensus on Bridges for Barriers to Insulin TherapySanjay Kalra, Samit Ghosal, Parag Shah
Scientific Reports|November 12, 2021
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)Samit Ghosal, Debasis Datta, Binayak Sinha
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 8, 2021
Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetesBinayak Sinha, Debasis Datta, Samit Ghosal
World Journal of Diabetes|November 1, 2016
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromeSanjay Chatterjee, Samit Ghosal, Saurav Chatterjee
Journal of Clinical Medicine|October 28, 2023
The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled TrialsSamit Ghosal, Shamita Ghosal, Anuradha Ghosal
Pageof 6